Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across multiple ...
FMC-376 demonstrated robust anti-tumor activity across preclinical models and led to deeper inhibition of KRAS downstream ...
Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients[i] New findings from this investigational study build on the strength of the data for amivantamab in ...
Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...
Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.
The peptide known as Fragment 176-191 (also sometimes linked with AOD-9604 in its analog forms) is a truncated portion of ...
Panelists discuss how understanding EGFR mutations has transformed the treatment landscape for non–small cell lung cancer ...
China Medical University leads a multi-institution team reporting that MTAP deficiency suppresses cytosolic nucleic acid ...
A phase 2 clinical study (NCT03974022)found that sunvozertinib (Zegfrovy) was efficacious in 2 different doses, but ...
Communication between epithelial and mesenchymal cells in pancreatic cancer leads to a poor prognosis. The molecular basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback